drugset / Trial / NCT06438367
TGRX-326 Pharmacokinetic Mass Balance
Phase 1
Completed
6 enrolled
Shenzhen TargetRx Co., Ltd.
The First Affiliated Hospital of Soochow University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a pharmacokinetic study for TGRX-326 on mass balance to evaluate distribution, metabolism and excretion of TGRX-326, an ALK inhibitor indicated for treatment of Non-small cell lung cancer.
Timeline
- Start
- 2024-06-26
- Primary completion
- 2024-07-08
- Completion
- 2024-07-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TGRX-326 | Unknown | 60 mg | Oral |